133 related articles for article (PubMed ID: 20421533)
1. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.
Walter RB; Alonzo TA; Gerbing RB; Ho PA; Smith FO; Raimondi SC; Hirsch BA; Gamis AS; Franklin JL; Hurwitz CA; Loken MR; Meshinchi S
J Clin Oncol; 2010 Jun; 28(17):2831-8. PubMed ID: 20421533
[TBL] [Abstract][Full Text] [Related]
2. VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia.
Bae MH; Oh SH; Park CJ; Lee BR; Kim YJ; Cho YU; Jang S; Lee JH; Kim N; Park SH; Lim JH; Seo EJ; Lee KH
Ann Hematol; 2015 Oct; 94(10):1631-8. PubMed ID: 26155911
[TBL] [Abstract][Full Text] [Related]
3. Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
Clin Cancer Res; 2015 Jul; 21(14):3187-95. PubMed ID: 25825478
[TBL] [Abstract][Full Text] [Related]
4. CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
Lamble AJ; Eidenschink Brodersen L; Alonzo TA; Wang J; Pardo L; Sung L; Cooper TM; Kolb EA; Aplenc R; Tasian SK; Loken MR; Meshinchi S
J Clin Oncol; 2022 Jan; 40(3):252-261. PubMed ID: 34855461
[TBL] [Abstract][Full Text] [Related]
5. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
Pollard JA; Loken M; Gerbing RB; Raimondi SC; Hirsch BA; Aplenc R; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
J Clin Oncol; 2016 Mar; 34(7):747-55. PubMed ID: 26786921
[TBL] [Abstract][Full Text] [Related]
6. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.
Loken MR; Alonzo TA; Pardo L; Gerbing RB; Raimondi SC; Hirsch BA; Ho PA; Franklin J; Cooper TM; Gamis AS; Meshinchi S
Blood; 2012 Aug; 120(8):1581-8. PubMed ID: 22649108
[TBL] [Abstract][Full Text] [Related]
7. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.
Becker PS; Kopecky KJ; Wilks AN; Chien S; Harlan JM; Willman CL; Petersdorf SH; Stirewalt DL; Papayannopoulou T; Appelbaum FR
Blood; 2009 Jan; 113(4):866-74. PubMed ID: 18927435
[TBL] [Abstract][Full Text] [Related]
8. High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia.
Ko SY; Park CJ; Park SH; Cho YU; Jang S; Seo EJ; Kim N; Kim DY; Koh KN; Im HJ; Seo JJ; Chi HS
Leuk Res; 2014 Jan; 38(1):65-70. PubMed ID: 24239175
[TBL] [Abstract][Full Text] [Related]
9. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
11. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
12. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
Vujkovic M; Attiyeh EF; Ries RE; Goodman EK; Ding Y; Kavcic M; Alonzo TA; Wang YC; Gerbing RB; Sung L; Hirsch B; Raimondi S; Gamis AS; Meshinchi S; Aplenc R
Blood; 2017 Jun; 129(23):3051-3058. PubMed ID: 28411282
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement].
Zhou JR; Zhang X; Zhao YL; Yang JF; Zhang JP; Cao XY; Lu Y; Liu DY; Lyu FY; Ouyang J; Lu PH
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):751-756. PubMed ID: 30369187
[No Abstract] [Full Text] [Related]
14. miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Ramamurthy R; Hughes M; Morris V; Bolouri H; Gerbing RB; Wang YC; Loken MR; Raimondi SC; Hirsch BA; Gamis AS; Oehler VG; Alonzo TA; Meshinchi S
Pediatr Blood Cancer; 2016 Dec; 63(12):2096-2103. PubMed ID: 27511899
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
16. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
Kottaridis PD; Gale RE; Frew ME; Harrison G; Langabeer SE; Belton AA; Walker H; Wheatley K; Bowen DT; Burnett AK; Goldstone AH; Linch DC
Blood; 2001 Sep; 98(6):1752-9. PubMed ID: 11535508
[TBL] [Abstract][Full Text] [Related]
17. Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia.
Sharawat SK; Gupta R; Raina V; Kumar L; Sharma A; Iqbal S; Bakhshi R; Vishnubhatla S; Bakhshi S
Cytometry B Clin Cytom; 2013; 84(6):390-7. PubMed ID: 23740774
[TBL] [Abstract][Full Text] [Related]
18. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Laszlo GS; Alonzo TA; Gudgeon CJ; Harrington KH; Kentsis A; Gerbing RB; Wang YC; Ries RE; Raimondi SC; Hirsch BA; Gamis AS; Meshinchi S; Walter RB
J Hematol Oncol; 2015 Oct; 8():115. PubMed ID: 26487643
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Childhood Acute Myeloid Leukemia With FLT3-ITD Mutation: The Experience of Children's Cancer Hospital Egypt, 2007-17.
Semary SF; Hammad M; Soliman S; Yassen D; Gamal M; Albeltagy D; Hamdy N; Mahmoud S
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e529-e541. PubMed ID: 32473792
[TBL] [Abstract][Full Text] [Related]
20. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
